• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Co-targeting of ACK1 and KIT triggers additive anti-proliferative and -migration effects in imatinib-resistant gastrointestinal stromal tumors
Biochim Biophys Acta Mol Basis Dis. 2023 Mar 13:166690. doi: 10.1016/j.bbadis.2023.166690. Online ahead of print.ABSTRACTMost gastrointestinal stromal tumors (GIST) harbor mutated receptor tyrosine kinase (RTK) KIT/PDGFRA, which provides an attractive therapeutic target. However, a majority of GISTs ultimately develop resistance to KIT/PDGFRA inhibitor imatinib, multiple therapeutic targets will be identified as a reasonable strategy in imatinib-resistant GISTs. Biological mechanisms of non-RTK activated CDC42 associated kinase 1 (ACK1) are still unclear, which has been found to be activated in GISTs. In the current report...
Source: Biochimica et Biophysica Acta - March 15, 2023 Category: Biochemistry Authors: Wangzhen He Liangliang Xu Jiongyan Ding Li Song Weili Yang Isabella Klooster Daniel F Pilco-Janeta C ésar Serrano Hongming Fang Guojun Jiang Xiaoyan Wang Jiren Yu Wen-Bin Ou Source Type: research

c-Abl phosphorylation of Yin Yang 1's conserved tyrosine 254 in the spacer region modulates its transcriptional activity.
In conclusion, we demonstrate the novel role of c-Abl kinase in regulation of YY1's transcriptional activity, linking YY1 regulation with c-Abl tyrosine kinase signaling pathways. PMID: 29807053 [PubMed - as supplied by publisher]
Source: Biochimica et Biophysica Acta - May 25, 2018 Category: Biochemistry Authors: Daraiseh SI, Kassardjian A, Alexander KE, Rizkallah R, Hurt MM Tags: Biochim Biophys Acta Source Type: research